Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.

Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.

J Cell Biochem. 2008 Feb 1;103(2):624-35.

PMID:
17562544
2.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. Review.

3.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
4.

Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.

Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W.

Steroids. 2009 Jul;74(7):586-94. doi: 10.1016/j.steroids.2008.11.020. Epub 2008 Dec 7. Review.

PMID:
19138696
5.

Endocrine resistance: what do we know?

Miller TW.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e37. Review.

6.

Her2 cross talk and therapeutic resistance in breast cancer.

Bender LM, Nahta R.

Front Biosci. 2008 May 1;13:3906-12. Review.

7.

Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.

Kurebayashi J, Okubo S, Yamamoto Y, Sonoo H.

Breast Cancer. 2004;11(1):38-41. Review.

PMID:
14718791
8.

Prospects for combining hormonal and nonhormonal growth factor inhibition.

Wakeling AE, Nicholson RI, Gee JM.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4350s-4355s; discussion 4411s-4412s. Review.

PMID:
11916224
9.

The biology of antihormone failure in breast cancer.

Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I.

Breast Cancer Res Treat. 2003;80 Suppl 1:S29-34; discussion S35. Review.

PMID:
14535532
10.

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.

Chien AJ, Rugo HS.

Breast Cancer Res Treat. 2013 Jan;137(1):1-12. doi: 10.1007/s10549-012-2328-6. Epub 2012 Nov 10. Review.

11.
12.

Clinical studies of apoptosis and proliferation in breast cancer.

Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE.

Endocr Relat Cancer. 1999 Mar;6(1):25-8. Review.

13.

Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment.

Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA Jr.

Endocr Relat Cancer. 1999 Mar;6(1):69-73. Review.

14.

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

Allen LF, Eiseman IA, Fry DW, Lenehan PF.

Semin Oncol. 2003 Oct;30(5 Suppl 16):65-78. Review.

PMID:
14613028
15.

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Segovia-Mendoza M, González-González ME, Barrera D, Díaz L, García-Becerra R.

Am J Cancer Res. 2015 Aug 15;5(9):2531-61. eCollection 2015. Review.

16.

Role of steroid hormones and growth factors in breast cancer.

Lai LC.

Clin Chem Lab Med. 2002 Oct;40(10):969-74. Review.

PMID:
12476934
17.

[Screening marine resources to find novel chemical inhibitors of disease-relevant protein kinases].

Baratte B, Serive B, Bach S.

Med Sci (Paris). 2015 May;31(5):538-45. doi: 10.1051/medsci/20153105016. Epub 2015 Jun 9. Review. French.

18.

Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update.

Lü JM, Nurko J, Weakley SM, Jiang J, Kougias P, Lin PH, Yao Q, Chen C.

Med Sci Monit. 2010 May;16(5):RA93-100. Review.

Items per page

Supplemental Content

Write to the Help Desk